The combination of anti–PD-1 Abs with agents targeting epidermal growth factor receptor and anaplastic lymphoma kinase has been associated with life-threatening irAEs in patients with advanced NSCLC (Lindeman et al., 2013; Spigel et al., 2018; Cheng et al., 2019; Xing et al., 2019). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.